|Bid||117.25 x 0|
|Ask||118.30 x 0|
|Day's Range||114.45 - 117.95|
|52 Week Range||97.49 - 136.70|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for ZEG.DU
WILMINGTON, Del., February 02, 2023--AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab-ekko) has been approved in the US for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma. TEZSPIRE is the only biologic approved for severe asthma with no phenotype (e.g. eosinophilic or allergic) or biomarker limitation within its approved label.1
The court ruled that drugmakers can limit their shipments of federally discounted drugs to pharmacies, in a blow to hospitals and clinics.
UK public borrowing increased by more than expected last month as the government ploughed billions into its subsidies for household bills.